Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

For post-prostatectomy radiation, what rectum, sigmoid, and bladder constraints do you use?

8
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · AdventHealth Cancer Institute

In these cases, I follow consensus guidelines for contouring the CTV_ProsBed and also contour out the sigmoid and any small bowel. I use whole organ volumes, not just wall contours, although there are published constraints for the rectal wall and bladder wall. There are a range of appropriate constr...

What treatment fields do use for heterotopic ossification prophylaxis?

3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mount Sinai Medical Center Miami

This is what I was told at HSS- Bridging ossification between the greater trochanter and pelvic bones locks the leg- this is the most important area to cover. Bridging ossifcation between the lesser trochanter and pelvic bones, I believe, presents a much more minor impairment. You dont have to block...

What volumes do you treat for unresectable tracheobronchial cancer?

4
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Cleveland Clinic

There is not a lot of literature on the management of primary tracheal cancer, since it is primarily a surgical disease. In the setting where the patient is inoperable or unresectable, then by first principles since it is an aerodigestive cancer, one can extrapolate the role of radiotherapy and chem...

In patients with oligometastatic disease, would you offer SBRT to a metastatic lymph node abutting the trachea and/or esophagus?

2
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic, Rochester

I have treated oligometastatic lymph nodes abutting esophagus and trachea. I do not do this routinely and the risks and benefits need to be weighed in terms of whether the patient is truly oligometastatic and if there are potentially effective systemic options.For these ultracentral locations, I fav...

How do you counsel patients regarding alcohol consumption following treatment of head and neck cancer?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Emory University School of Medicine

I always tell patients that there is no known safe amount of alcohol consumption, especially regarding the risk of developing another head and neck cancer. Most patients who consume alcohol after head and neck radiation therapy often tell me that it does not provide the same enjoyment as before due ...

How would you sequence adjuvant chemo-immunotherapy (paclitaxel/carbo/pembro or paclitaxel/carbo/dostarlimab) with EBRT and vaginal cuff brachytherapy in advanced uterine cancer that meets clinical criteria for both EBRT and chemo-IO?

7
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Abramson Cancer Center, University of Pennsylvania

A common misapplication of RUBY/GY018 is giving IO in patients with non-measurable advanced uterine cancer. Radiation as part of the trial was not included in these studies. The role for chemo-IO vs chemo alone (with or without radiation) for high risk non-measurable uterine cancer was tested in GOG...

Given the results of KEYNOTE-A18, do you plan to recommend adding pembrolizumab to primary chemoradiotherapy for advanced stage cervical cancer?

4
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Vanderbilt-Ingram Cancer Center

Until the paper gets published, we won't really know a lot of details that may influence the potential utility of this regimen. It has an abstract/presentation and has recently received FDA approval.It is a relatively 'newer' idea in improving outcomes that we as an institution are open to start off...

How are you using the Decipher score in the definitive setting for prostate cancer?

7
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center

This is an excellent question.Before I can answer the question directly, you must ask yourself how do you currently decide who to give ADT to with RT?The easy answer is that you use RCTs to choose who to give short-term and long-term ADT to. However, I wish it was that easy.Lets take RTOG 9408- It i...

How do you manage early stage I uterine serous carcinoma?

5
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Texas MD Anderson Cancer Center

The management of these patients remains controversial. The data are conflicting and treatment choices tend to be based more on impressions than solid data. Most clinicians advocate chemotherapy although randomized trials have not clearly shown benefit for this subset. For stage IA, we typically tre...

Would you consider radiation omission for a patient with a Stage I breast cancer with an elevated Oncotype Dx?

7
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Rutgers Robert Wood Johnson Medical School

I would offer the patient treatment based on the fact that she is in her 60s with a presumably long life expectancy, a high grade lesion, and radiation will lower her risk of local recurrence significantly. Even with a lower Oncotype, radiation will lower the risk of recurrence significantly accordi...